The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients

J. J. Kiser, M. L. Carten, C. L. Aquilante, P. L. Anderson, P. Wolfe, T. M. King, T. Delahunty, L. R. Bushman, C. V. Fletcher

Research output: Contribution to journalArticlepeer-review

170 Scopus citations


We determined the effects of lopinavir/ritonavir on tenofovir renal clearance. Human immunodeficiency virus-infected subjects taking tenofovir disoproxil fumarate (TDF) were matched on age, race, and gender and were enrolled into one of the following two groups: group 1: subjects taking TDF plus lopinavir/ritonavir plus other nucleoside reverse transcriptase inhibitors (NRTIs); group 2: subjects taking TDF plus NRTIs and/or non-NRTIs but no protease inhibitors. Twenty-four-hour blood and urine collections were carried out in subjects for tenofovir quantification. Drug transporter genotype associations with tenofovir pharmacokinetics were examined. In 30 subjects, median (range) tenofovir apparent oral clearance, renal clearance, and fraction excreted in urine were 34.6 l/h (20.6-89.5), 11.3 l/h (6.2-22.6), and 0.33 (0.23-0.5), respectively. After adjusting for renal function, tenofovir renal clearance was 17.5% slower (P=0.04) in subjects taking lopinavir/ritonavir versus those not taking a protease inhibitor, consistent with a renal interaction between these drugs. Future studies should clarify the exact mechanism and whether there is an increased risk of nephrotoxicity.

Original languageEnglish (US)
Pages (from-to)265-272
Number of pages8
JournalClinical Pharmacology and Therapeutics
Issue number2
StatePublished - Feb 2008
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients'. Together they form a unique fingerprint.

Cite this